These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22812559)

  • 1. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models.
    Mauskopf J; Talbird S; Standaert B
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):357-71. PubMed ID: 22812559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-benefit comparisons of investments in improved water supply and cholera vaccination programs.
    Jeuland M; Whittington D
    Vaccine; 2009 May; 27(23):3109-20. PubMed ID: 19428925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of varicella vaccination of healthcare workers.
    Chodick G; Ashkenazi S; Livni G; Lerman Y
    Vaccine; 2005 Oct; 23(43):5064-72. PubMed ID: 16046036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.
    Shafie AA; Yeo HY; Coudeville L; Steinberg L; Gill BS; Jahis R; Amar-Singh Hss
    Pharmacoeconomics; 2017 May; 35(5):575-589. PubMed ID: 28205150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of the introduction of a pre-erythrocytic malaria vaccine into the expanded program on immunization in sub-Saharan Africa: analysis of uncertainties using a stochastic individual-based simulation model of Plasmodium falciparum malaria.
    Maire N; Shillcutt SD; Walker DG; Tediosi F; Smith TA
    Value Health; 2011 Dec; 14(8):1028-38. PubMed ID: 22152171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs.
    Brisson M; Edmunds WJ
    Med Decis Making; 2006; 26(5):434-46. PubMed ID: 16997923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
    Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z;
    Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease.
    Dasbach EJ; Elbasha EH; Insinga RP
    Epidemiol Rev; 2006; 28():88-100. PubMed ID: 16740585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.
    Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ
    Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective cost-effectiveness analyses for polio vaccination in the United States.
    Thompson KM; Tebbens RJ
    Risk Anal; 2006 Dec; 26(6):1423-40. PubMed ID: 17184390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia.
    De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M
    Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The economics of routine childhood hepatitis A immunization in the United States: the impact of herd immunity.
    Armstrong GL; Billah K; Rein DB; Hicks KA; Wirth KE; Bell BP
    Pediatrics; 2007 Jan; 119(1):e22-9. PubMed ID: 17200247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
    Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
    Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.
    Navas E; Salleras L; Domínguez A; Ibáñez D; Prat A; Sentís J; Garrido P
    Vaccine; 2007 Apr; 25(16):3233-9. PubMed ID: 17324489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.